Rubella virus-associated granulomas commonly occur in immunocompromised individuals, exhibiting a diverse range of clinical presentations. These manifestations can vary from predominantly superficial cutaneous plaques or nonulcerative nodules to more severe deep ulcerative lesions, often accompanied by extensive necrosis and significant tissue destruction. TAP1 deficiency, an exceedingly rare primary immune-deficiency disorder, presents with severe chronic sino-pulmonary infection and cutaneous granulomas. This report highlights the occurrence of rubella virus-associated cutaneous granulomas in patients with TAP1 deficiency. Notably, the pathogenic mutation responsible for TAP1 deficiency stems from a novel genetic alteration that has not been previously reported. This novel observation holds potential significance for the field of diagnosis and investigative efforts in the context of immunodeficiency disorders.
Recent studies have reported skin microbiome dysbiosis in patients with photodermatoses, featuring enriched Staphylococcus aureus colonization and decreased microbiome diversity. We propose that ultraviolet radiation (UVR), along with atypical antimicrobial peptides, may exert selective pressure on the skin microbiome, while cytokine dysregulation and a reduction in commensal bacteria amplify microbial dysbiosis. Dysbiotic microorganisms further release pathogen-associated patterns and virulence factors, and activate tissue-resident memory T cells, which collectively contribute to local inflammation. These mechanisms establish the skin microbiome as a potential target for early intervention. Potential therapeutic strategies may include antibiotics, phototherapy, bleach baths, phage therapy, and microbiota-based therapies. This review integrates current findings from microbial ecology, molecular biology, and host immunology to outline a conceptual framework linking UVR exposure, microbiome alterations, and cutaneous immune responses, while emphasizing the current limitations and evidence gaps in this field.
Introduction: JAK inhibitors are well-established for their utilization in the treatment of autoinflammatory diseases, with the JAK1 inhibitor abrocitinib primarily employed in the management of atopic dermatitis. To provide new clinical therapeutic experience for patients with chronic actinic dermatitis (CAD), reveal the inflammatory pathways that may be involved in the treatment of CAD with abrocitinib and to provide clues for exploring the pathogenesis of CAD. Methods: In a 3-month longitudinal study, we recorded and analyzed laboratory test data and clinical severity assessments in 16 patients diagnosed with chronic actinic dermatitis treated with abrocitinib. And the plasma samples of 6 patients before and after treatment were analyzed proteomically using Olink inflammation panel. Results: After 12 weeks of treatment, there was a significant decrease in disease severity scores of 16 patients. No serious adverse events were identified throughout the course of treatment. Significant changes in several inflammatory factors such as EN-RAGE, MCP-3, MCP-4, IL-13, CCL4, FGF21 and TNFRSF9 were observed after treatment. Discussion: The analysis of our data demonstrates that abrocitinib may be an effective therapeutic option in the management of CAD. IL-13 and CCL-4 might be the core effective factors after the therapy.
Severe misdiagnosis of scabies can result in prolonged symptoms, inappropriate use of immunosuppressive therapy, secondary infections, and transmission within an institution. Hospitalized patients frequently present with atypical morphology or distribution, leading to uncertainty in diagnosis. This study aimed to identify clinical characteristics associated with severe misdiagnosis of scabies using a study-defined pragmatic grading system developed to capture diagnostic delay, inappropriate treatment exposure, and adverse clinical consequences. We performed a retrospective review of 41 patients admitted to the hospital and subsequently confirmed to have scabies. Because no validated grading system currently exists for the severity of scabies misdiagnosis, we applied a study-defined, pragmatic four-level classification (Levels 0-3) based on diagnostic delay, inappropriate treatment exposure, and clinical consequences. Levels 2 and 3 were defined as severe misdiagnosis. Univariate logistic regression was performed to assess factors associated with severe misdiagnosis, whereas univariate ordinal logistic regression (proportional odds model) was performed to explore associations across the entire severity grading system. Severe misdiagnosis was identified in 10 of 41 patients (24.4%). Interdigital involvement was associated with lower odds of severe misdiagnosis (OR 0.048, 95% CI 0.008-0.297; P = 0.001), whereas generalized involvement was associated with higher odds of severe misdiagnosis (OR 7.27, 95% CI 1.31-40.42; P = 0.023). Ordinal regression showed directionally consistent findings: generalized involvement was associated with higher misdiagnosis grades (common OR 14.74; P = 0.002), whereas interdigital involvement was associated with lower misdiagnosis grades (common OR 0.106; P = 0.003). Age showed a non-significant trend toward higher misdiagnosis severity. Routine laboratory tests showed limited discriminatory value. In this retrospective hospital-based cohort, absence of classical interdigital involvement and generalized distribution were associated with higher grades of scabies misdiagnosis in univariate exploratory analyses. Bullous morphology also showed a non-significant trend toward higher misdiagnosis severity. These findings are hypothesis-generating and most applicable to similar hospitalized populations. Targeted examination of classic sites or empirical treatment when a diagnosis is suspected remains crucial, especially in cases of widespread or atypical presentations. Larger prospective studies are needed to validate the proposed study-defined grading system and to determine whether these clinical patterns can reliably guide diagnostic decision-making.